diagnostic - Nanbiosis

U2. Custom Antibody Service Unit (CAbS)

U2. Custom Antibody Service (CAbS)

Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
Scientific Coordinator: Dr. Nuria Pascual npdqob@cid.csic.es
Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
Phone: +34 934 006 100
Web: IQAC- CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus. Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

The NANBIOSIS Unit 2 works under the ISO9001 certification for standard quality control system QUALITY POLICY

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U2. Services & Rates

Equipments

Active projects

	Title	Fundin: Organism	Call: Funding source	Role
SAF2017-90810-REDI	Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II	Agencia Estatal de Investigación (AEI)	Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017	Partner
PICCOLO-732111	Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support	European Commission-H2020	H2020-ICT-2016-1	Partner
0624_2IQBIONEURO_6_E	Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases	European Union Interreg : European Territorial Co-operation	POCTEP Interreg España-Portugal	Partner

Other projects

Ref	Title	Funding Organism	Unit Role
SAF2015-67476-R	Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS)	Ministerio de Economía y Competitividad	Participant
PIE1400061	Molecular links between diabetes and neurodegenerative diseases	ISCIII	Oberver
2014SGR1484	Consolidated Research Group	Generalitat de Catalunya	Participant
FP7-614168	Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP)	European Commission	Oberver
CI16-00031 Caixa Impulse	A new approach for the detection of Pseudomonas aeruginosa	CaixaBank	Participant
MSCA-ITN2015-675412	New Diagnostics for Infectious Diseases	European Commission	Participant
TECCTP15-1-0011	Ajuda acreditació Tecnio del grup Nb4D	ACCIÓ: Generalitat de Catalunya	Others

Publications

2016

Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

05 Nov

NANBIOSIS Showcases Biosensor Innovation as Sponsor of EBS2025 in Tarragona

NANBIOSIS sponsored EBS2025 in Tarragona, showcasing the advances of Units 2 & 29 in antibodies and oligonucleotides for next-gen biosensors. Tarragona, October 2025 — NANBIOSIS proudly participated as an official sponsor of the 5th European Biosensor Symposium (EBS2025), held from 26 to 29 October 2025 in Tarragona. The international event, chaired by Prof. Dr. M. Pilar Marco (IQAC-CSIC / CIBER-BBN and Scientific Director of Unit 2 of NANBIOSIS), brought together hundreds of researchers, engineers and industry leaders to discuss the latest advances in biosensors, nanotechnology, microfluidics, and diagnostic devices. Through its Unit 2 and Unit 29, NANBIOSIS highlighted its key[...]

04 Nov

NANBIOSIS Strengthens Internal Collaboration at 2025 Networking Event in Cáceres

NANBIOSIS held its 2025 networking event in Cáceres to boost collaboration among Units in biomaterials, nanomedicine, and biomedical research. Cáceres, October 2025 — From 22 to 24 October 2025, the Singular Scientific and Technical Infrastructure (ICTS) NANBIOSIS held its annual internal networking event at the Centro de Cirugía de Mínima Invasión Jesús Usón (CCMIJU) in Cáceres, Spain. The event brought together Unit coordinators, researchers, and technical staff from across Spain to foster collaboration, share scientific progress, and explore new opportunities for joint projects in biomedical research, nanomedicine, and biotechnology. A meeting to boost collaboration across NANBIOSIS Units The three-day event[...]

16 Oct

NANBIOSIS at BIOSPAIN 2025: Strengthening public-private bridges for translational nanomedicine

NANBIOSIS joins BIOSPAIN 2025 with ISCIII and CIBER, boosting biotech partnerships and showcasing early HTA and ARISTOS innovations. Barcelona, October 2025 — Last week NANBIOSIS took part in BIOSPAIN 2025 (Fira de Barcelona Montjuïc), joining forces at the ISCIII / CIBER stand to showcase our facilities and to deepen collaborations with industry partners, users and strategic allies. Over three intensive days the NANBIOSIS and CIBER representatives held multiple meetings with potential private partners and technology users to accelerate translation of nanomedicine and biomedical technologies. Record edition: numbers that matter BIOSPAIN 2025 closed as the largest edition to date: more than[...]

05 Aug

HPLC: What It Is, How It Works, and Its Applications in Modern Biotech

Discover what HPLC is, how it works, and why it’s essential in analytical chemistry and biotechnology. Learn about real applications like LC/MSD iQ integration for antibody purification. What is HPLC? Understanding High-Performance Liquid Chromatography High-Performance Liquid Chromatography (HPLC) is one of the most powerful analytical techniques used in chemistry, biochemistry, and biotechnology. From pharmaceutical quality control to the purification of cutting-edge biotechnological products, HPLC provides high-resolution separation and precise quantification of complex mixtures. Its precision, sensitivity, and versatility have made it indispensable in both research and industrial settings. This article explores how HPLC works, its key components, real-world applications —including[...]

30 Jul

Protein Purification Methods: Advanced Techniques and Automation with ÄKTA Pure

Explore modern protein purification methods with a special focus on automated systems like ÄKTA Pure. Learn how advanced chromatography workflows are transforming antibody production, diagnostics, and biotech applications. What is protein purification and why does it matter? Protein purification is a fundamental process in biotechnology, biomedical research, and pharmaceutical production. It involves isolating a specific protein of interest from a complex mixture, such as a cell lysate, while preserving its structure and function. This process is critical because the quality, purity, and yield of proteins directly impact downstream applications such as drug development, diagnostic assays, and therapeutic research. In t[...]

21 May

NANBIOSIS to participate in the new edition of the European Biosensors Symposium 2025

NANBIOSIS will join EBS2025 in Tarragona as organizer and sponsor, with a stand to showcase its services in biosensors and nanobiomedicine. Tarragona, october 2025. NANBIOSIS will be actively participating in the European Biosensors Symposium (EBS) 2025, which will take place from 26th to 29th October in Tarragona, Spain. The event, which brings together leading researchers and innovators in the field of biosensors, provides a platform to discuss the latest scientific and technological advances, promote collaboration, and explore new opportunities for innovation. This year, NANBIOSIS is proud to be part of the organization and will also be present as an officia[...]

21 Jun

Prof. Pilar Marco takes helm of CIBER-BBN: Leading the future of Bioengineering, Biomaterials, and Nanomedicine

Barcelona, June 21, 2024 – Prof. Pilar Marco has been appointed as the new head of the Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) thematic area at the Centro de Investigación Biomédica en Red (CIBER). This prestigious appointment was confirmed during the CIBER Governing Board meeting held on June 20, 2024. Prof. Marco succeeds Ramón Martínez, bringing a wealth of expertise and a distinguished track record in biomedical research for more than a decade. Prof. Marco is a research professor at the Consejo Superior de Investigaciones Científicas (CSIC), specifically at the Institute of Advanced Chemistry of Catalonia (IQAC) in Barcelona. Additionally, s[...]

28 Feb

The fight against rare respiratory diseases: New hope in detection and treatment

Researchers from IQAC-CSIC advance towards faster detection and treatment of cystic fibrosis and rare respiratory diseases, improving patient outcomes. 28 February 2024, IQAC-CSIC (Barcelona) Cystic Fibrosis (CF) is a progressive autosomal recessive disease. It is caused by a mutation in the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, disrupting its exocrine activity. While CF affects various organs, its impact on the lungs is particularly severe. This disease leads to the accumulation of thick, sticky mucus, obstructing airways and trapping bacteria, resulting in significant infections and extensive lung damage. Consequently, individuals with CF are highly susceptible to respiratory[...]

• Read More

U29. Oligonucleotide Synthesis Platform (OSP)

U29. Oligonucleotide Synthesis Platform (OSP)

Scientific Director: Prof. Ramon Eritja: recgma@cid.csic.es
Scientific Coordinator: Dr. Anna Aviñó: aaagma@cid.csic.es
Entities: Institute of Avanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC)
Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
Phone: +34 934 006 145
Web: IQAC- CSIC

Order request

Description

This unit is coordinated by the Nucleic Acids Chemistry Group at the Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC) and has the equipment needed for the production of oligonucleotides at low scale (mg to mg), purification, characterization and post-synthesis modification. The service counts with laboratories for synthesis and modification of oligonucleotides including DNA/RNA synthesizer, analytical and semi-preparative HPLC equipment for the purification and characterization of oligonucleotides. The service will focus in providing expert opinion to researchers as well as the production of tailored oligonucleotides. Routine synthesis of oligonucleotides used as primers will not be produced as there is a large number of commercial sources that provide a quick and low price service. The oligonucleotide synthesis platform will focus in providing modified oligonucleotides (ONs) that are difficult to obtain from commercial sources. These include microgram to milligram amounts of DNA and RNA derivatives carrying several modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptors ligands, carbohydrates and peptides designed for therapeutic or diagnostic purposes. The facility benefits from the wide experience of Prof. Ramon Eritja that has more than 30 years expertise in the development of modified oligonucleotides.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U29. Services & Rates

Equipments

Active projects

Ref	Title	Fundin Organism	Role
CTQ2017-84415-R	STUDY OF ADN STRUCTURES WITH BIOMEDICAL POTENTIAL	MINECO	Coordinator

Other projects

Ref	Title	Fundin Organism	Role
SBPLY/17/180501/000376	Development and validation of new intelligent administration systems of RNAs in the injured spinal cord: application in a neuroprotective therapy based on miR-138	Junta de Castilla-La Mancha	Participant
BIO2017-92113-EXP	New tailored microRNA-based antifungal agents for crop protection	MINECO - Explora-	Participant
CA17103	CA17103 Delivery of antisense RNA therapeutics (DARTER)	C.C.E.E. COST Action	Participant
AC18/00046	Monitoring of Acquired Brain Injury and recovery of biomarkers by the combined label-free NanoSensing of multiple circulating molecules (ABISens).	Euronanomed-III (ERA-Net cofund action on Nanomedicine)	Participant
CSIC-COV19-041	Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV)	Consejo Superior de Investigaciones Científicas (CSIC)	Participant
Prometeo/2020/081	Use of microRNA modulators as experimental therapies in type 1 myotonic dystrophy	Generalitat Valenciana	Participant

Publications

2019

“Synthesis of oligonucleotides carrying nucleic acid derivatives of biomedical and structural interest” Eritja, R., Aviñó, A., Fàbrega, C., Alagia, A., Jorge, A.F., Grijalvo, S. In “Enzymatic and chemical synthesis of nucleic acid derivatives” (Fernández Lucas and Camarasa Eds) Willey-VCH Verlag, Weinheim (Germany), pp 237-258, (2019).

Cationic niosomes as non-viral vehicles for nucleic acids. Challenges and opportunities in gene delivery. Grijalvo, S., Puras, G., Zárate, J., Sainz-Ramos, M., AL Qtaish, N., López, T., Mashal, M., Attia, N., Díaz Díaz, D., Pons, R., Fernández, E., Pedraz, J.L., Eritja, R. Pharmaceutics, 11(2), 50 (2019).

“Parallel clamps and polypurine hairpins (PPRH) for gene silencing and triplex-affinity capture: design, synthesis and use” Aviñó, A., Eritja, R., Cuidad, C., Noe, V. Current Protocols on Nucleic Acid Chemistry, e78 (2019).

“Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy” Aviñó, A., Unzueta, U., Cespedes, M.V., Casanova, I., Vázquez, E., Villaverde, A., Mangues, R., Eritja, R. ChemistryOpen, 8, 382-387 (2019).

“The small interfering RNAs (siRNAs) in cancer therapy: nano-based approach” Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C.D., Memari, F., Miri, S.R., Rad, M.R., Marmari, V. Int. J. Nanomedicine, 14, 3111-3128 (2019).

“The origins and the biological consequences of the Pur/Pyr DNA•RNA asymmetry” Terrazas, M., Genna, V., Portella, G., Villegas, N., Sánchez, D., Arnan, C., Pulido-Quetglas, C., Johnson, E., Guigó, R., Brun-Heath, I., Aviñó, A., Eritja, R., Orozco, M. Chem., 5, 1619-1631 (2019).

“On the race for more stretchable and tough hydrogels” Grijalvo, S., Eritja, R., Díaz Díaz, D. Gels, 5, 24 (2019).

“Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes” Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Control. Rel., 304, 181-190 (2019).

“Study of conformational transitions of i-motif DNA using time-resolved fluorescence and multivariate analysis methods” Benabou, S., Ruckebusch, C., Sliwa, M., Aviñó, A., Eritja, R., Gargallo, R., de Juan, A. Nucleic Acids Res., 47, 6590-6605 (2019).

“Expanding the limits of amide-triazole isosteric substitution in bisamide-based physical gels” Tautz, M., Torras, J., Grijalvo, S., Eritja, R., Saldías, C., Alemán, C., Díaz Díaz D. RSC Adv., 9, 20841-20851 (2019).

“Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity” Aviñó, A., Jorge, A.F., Huertas, C.S., Cova, T.F.G.G., Pais, A., Lechuga, L.M., Eritja, R., Fàbrega, C. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).

“Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro” Attia, N., Mashal, M., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Drug Delivery Science Technol., 53, 101219 (2019).

“Stabilization of c-KIT G-quadruplex DNA structures by the RNA polymerase I inhibitors BMH-21 and BA-41” Mazzini, S., Gargallo, R., Musso, L., De Santis, F., Aviñó, A., Scaglioni, L., Eritja, R., Di Nicola, M., Zunino, F., Amatulli, A., Dallavalle, S. Int. J. Mol. Sci., 20, 4927 (2019).

“Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord” Grijalvo, S., Nieto-Díaz, M., Maza, R.M., Eritja, R., Díaz Díaz, D. Biotech J., 14, e1900275 (2019).

“A pH-dependent bolt involving cytosine bases located in the lateral loops of antiparallel G-quadruplex structures within the SMARCA4 gene promotor” Benabou S., Mazzini, S., Aviñó, A., Eritja, R. Gargallo, R. Sci. Rep., 9, 15807 (2019).

2018

Selective depletion of metastatic stem cells as therapy for human colorectal cancer. Céspedes, M.V., Unzueta, U., Aviñó, A., Gallardo, A., Álamo, P., Sala, R., Sánchez-Sardi, A., Casanova, I., Mangues, M.A., Lopez-Pousa, A., Eritja, R., Villaverde, A., Vázquez, E., Mangues, R. EMBO Mol. Med., 10, e8772 (2018).

DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Jorge, A.F., Aviñó, A., Pais, A.A.C.C., Eritja, R., Fàbrega, C. Nanoscale, 10, 7238-7249 (2018).

Exploring PAZ/3’-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Alagia, A., Jorge, A.F., Aviño, A., Cova, T.F.G.G., Crehuet, R., Grijalvo, S., Alberto Pais, A.A.C.C., Eritja, R. Chem. Sci., 9, 2074-2086 (2018).

DNA origami-driven lithography for patterning on gold surfaces with sub-10 nanometer resolution. Gállego, I., Manning, B., Prades, J.D., Mir, M., Samitier, J., Eritja, R. Adv. Mat., 29, 1603233 (2017).

Glucose-nucleobase pseudo base pairs as a new biomolecular interaction in a DNA context. Vengut-Climent, E., Gómez-Pinto, I., Lucas, R., Peñalver, P., Aviñó, A., Fonseca-Guerra, C, Bickelhaupt, F.M.., Eritja, R., González, C., Morales, J.C. Angew. Chem. Int. Ed. Engl., 55, 8643-8647 (2016).

News U29

05 Nov

NANBIOSIS Showcases Biosensor Innovation as Sponsor of EBS2025 in Tarragona

04 Nov

NANBIOSIS Strengthens Internal Collaboration at 2025 Networking Event in Cáceres

27 Aug

New book release: Second edition of Nucleic Acids Chemistry explores advances in biomedicine and nanotechnology

Second edition of Nucleic Acids Chemistry explores novel modifications and RNA therapeutics for biomedicine, nanomedicine, and nanotechnology. Barcelona, September, 2025 — The second edition of the book Nucleic Acids Chemistry. Modifications and Conjugates for Biomedicine and Nanotechnology will be released on September 1st, 2025, published by De Gruyter (Berlin). This updated volume expands on the successful first edition published in 2021, incorporating recent scientific advances in nucleic acids research with applications in biomedicine, nanomedicine, and nanotechnology. With 414 pages of updated content (ISBN: 978-3-11-142468-2), the book provides a comprehensive overview of nucleic acid modifications, backbone engineering, and therapeutic conjugates, as[...]

08 Mar

The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024

Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]

29 Feb

The new official webpage of RED-DM is coordinating research efforts in Myotonic Dystrophy

NANBIOSIS introduces the new webpage of RED-DM, uniting experts to combat Myotonic Dystrophy. Highlighting Ramón Eritja’s group’s pivotal role. 29 February 2024, IQAC-CSIC (Barcelona) In a significant stride toward addressing the challenges posed by Myotonic Dystrophy, the Translational Genomics Group of the INCLIVA Health Research Institute (associated with the Valencia Clinical Hospital) and the University of Valencia (BIOTECMED Institute) have spearheaded the establishment of the Red Temática Nacional en Distrofia Miotónica tipo 1 (National Thematic Network in Myotonic Dystrophy Type 1). This progressive and degenerative disease, also referred to simply as DM1, is currently incurable and underdiagnosed. In addition, it[...]

15 Feb

Women in NANBIOSIS part 1: Anna Aviñó, from Curiosity to Innovation

Anna Aviñó speaks about her journey as a researcher and her captivating oligonucleotides. This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024 and Woman’s Day 2024. For more interviews, visit our news section here. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona (Spain) Could you share with us a bit about your research area and the projects you are currently working on? I am a chemist specializing in nucleic acid chemistry. These compounds are wonderful, I would say unique; not only do they contain genetic information, but they[...]

06 Feb

‘Magic Bullets’ Against Cancer: Unveiling the Potential of DNA Nanoparticles

DNA nanoparticles to selectively target tumor tissues through precise control of the synergies between transported drugs. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona. The team led by Drs. Carme Fàbrega and Ramón Eritja, in close collaboration with 3 units of the NANBIOSIS ICTS, has developed a new strategy to improve the efficacy and reduce the toxicity of anticancer drugs. They have chemically linked several cytotoxic drugs, currently used in the treatment of various types of tumors, to DNA nanostructures. These structures selectively target cancerous tissues through folate receptors. This tactic allows precise control of drug concentration and exploits their combined effect. The results[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

• Read More

Nanbiosis

You are here : Home / Archive for "diagnostic"

U2. Custom Antibody Service (CAbS)

Description

Services

Equipments

Active projects

Other projects

Publications

News U2

U29. Oligonucleotide Synthesis Platform (OSP)

Description

Services

Equipments

Active projects

Other projects

Publications

News U29